RxDoctor Payments Data

Melissa Anderson, MD

Allergy & Immunology · Greenville, SCNPI 1861987299

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Sanofi at 26.7% of the total. 2025 is the largest year on record at $1,943, more than ten times the $18 reported in 2021. That places this record below the midpoint for allergy & immunology clinicians in SC, where the typical reported total is $7,297.

$3,429in general payments, 2019–2025

Across 173 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$916
  • AstraZeneca$344
  • CSL Behring$316
  • Genentech USA, Inc.$278
  • GSK$224
  • Grifols USA, LLC$179
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,429 in reported general payments places this provider in the 30th percentile of 46 allergy & immunology providers in South Carolina.

See all allergy & immunology providers in South Carolina

Medicare billing

Part B allowed, 2024
$147,342
Medicare patients
392
Services billed
7,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,077
Epinephrine26$3,453
Azelastine Hcl79$2,897
Ipratropium Bromide56$1,706
Albuterol Sulfate HfaAlbuterol Sulfate30$810
Montelukast Sodium27$375
Famotidine19$192
Fluticasone Propionate23$189
Triamcinolone Acetonide11$47
Prednisone14$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$224$11,07713 claims
Hikma Pharmaceuticals USAEpinephrine$14$3,45326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 46 allergy & immunology providers in South Carolina.

Other allergy & immunology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →